Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

NCT06008119 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: Tunlametinib plus Vemurafenib
DRUG: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab

Sponsor

Shanghai Kechow Pharma, Inc.